Vol 4, No 5 (2015)
Case report
Published online: 2015-12-18

open access

Page views 912
Article views/downloads 1583
Get Citation

Connect on Social Media

Connect on Social Media

Novel therapeutic option in type 2 diabetes patients — practical experience with canagliflozin, SGLT2 inhibitor

Alicja Milczarczyk, Edward Franek, Edyta Cichocka, Janusz Gumprecht
Diabetologia Kliniczna 2015;4(5):204-209.

Abstract

Sodium glucose co-transporter 2 inhibitors (SGLT2i) were introduced into Polish Diabetes Association Clinical Guidelines in 2014 in combination with other antihyperglycemic agents. In our paper we describe clinical cases of using SGLT2 inhibitor — canagliflozin as an add-on therapy in two different combinations. The first case refers to the patient with inadequately controlled type 2 diabetes, associated with obesity, hypertension and dyslipidemia. Due to the profile of the patient it was decided to add canagliflozin to insulin therapy and metformin, which resulted in improvements in glycemic control, body weight reduction, as well as reduction in insulin dose. In the second patient treated with metformin in monotherapy, addition of canagliflozin was associated with improved glycemic control and reduced body weight, which positively affected patient’s motivation to continue treatment. Through the mechanism of targeting kidney instead of pancreas it is possible to combine this group of drugs with virtually all currently available antihyperglycemic treatments and in patients at various stages of type 2 diabetes.

Article available in PDF format

View PDF (Polish) Download PDF file